Introduction
Lung cancer has been a major health problem worldwide, accounting for a global incidence of 1.2 million new cases yearly and a staggering mortality of 1.1 million deaths in 2001. 1 In Hong Kong, lung cancer has remained the commonest malignancy in men and the third commonest in women, with a total of 4,135 new cases in 2005. Being the commonest cancer killer in both sexes, there were 3,686 deaths in the same year (Hong Kong Cancer Registry). The majority (>80%) of lung cancers are non-small cell carcinomas (NSCLC), which are predominantly in advanced or metastatic stages upon presentation. The high mortality is mainly ascribed to disease recurrence after curative lung resection and the lack of effective treatment for advanced disease. The overall treatment plan for NSCLC largely depends on clinical staging: curative lung resection for early stages (mainly stage I and II), combined chemoradiotherapy for locally advanced stages (mainly stage III), and systemic platinum-based chemotherapy for advanced metastatic stages (mainly stage IIIB and IV). Prior to our understanding of molecular tumour biology of NSCLC, the use of systemic chemotherapy has been targeting at rapidly growing tumour cells in a rather non-specific fashion. In principle, a more specific approach that works on salient molecular pathways for tumourigenesis, i.e. targeted therapy, may help to enhance clinical efficacy while minimising toxicities related to damage of normal tissues. This review serves to summarise the current state-of-the-art targeted approach in the treatment of NSCLC.
Anti-angiogenesis
The majority of patients with NSCLC presented with unresectable diseases, due to regional involvement of mediastinal lymph nodes, pleural or pericardial malignant effusion, or distant metastases. In the past decade, systemic chemotherapy has become the standard first-line treatment for those with malignant effusion or distant metastases. 2 In such patients with good performance status, a combination of platinum (cisplatin or carboplatin) and a newer generation chemotherapeutic agent (e.g. paclitaxel, docetaxel or gemcitabine) has been well-documented to improve overall survival, disease-free survival and quality of life compared to best supportive care alone or older generation chemotherapy combinations. 3 However, the improvement in survival is considered modest (on average 2 months prolongation of median survival compared to best supportive care alone) and the time to disease progression is usually within a few months since commencement of chemotherapy. 4 In general, malignant tumours cannot grow beyond 2mm in size without developing a vascular supply. 5 The process of neovascularisation also provides a channel for tumour cells to migrate to the systemic circulation and subsequent development of distant metastases. In fact, tumours remain dormant and unable to metastasise in the absence of a functional v a s c u l a r s u p p l y . 6,7 A n g i o g e n e s i s , w h e t h e r physiological or pathological, is controlled by the balance between proangiogenic and antiangiogenic factors 8 (Table 1 ). The most important proangiogenic factor involved in tumour angiogenesis is vascular endothelial growth factor (VEGF), which has become the target for antiangiogenic therapy in NSCLC. 9 The VEGF pathway can be inhibited by agents that target VEGF or VEGF receptors. In particular, bevacizumab (Avastin TM ) is an anti-VEGF recombinant humanised monoclonal antibody, which contains the human immunoglobulin G1 framework (93%) and murine VEGF-binding complementarity-determining regions (7%) blocking the binding of VEGF to its receptors and subsequent downstream biologic activities. A randomised phase II study of bevacizumab in combination with carboplatin and paclitaxel or same chemotherapy alone as first-line treatment in patients with stage IIIB or IV NSCLC has demonstrated superior response rate, time to progression and survival in the bevacizumab combination arm, with increased risk of life-threatening haemoptysis in squamous cell carcinoma. 10 In view of these promising results, a recent randomised phase III study (E4599) was conducted comparing the combination of bevacizumab with chemotherapy (carboplatin and paclitaxel) versus chemotherapy alone in the treatment of advanced chemonaive nonsquamous NSCLC. 11 There was a statistically significant survival advantage that favoured the bevacizumab combination arm (median survival 12.3 months vs 10.3 months in bevacizumab vs chemotherapy alone arms, hazard ratio for death 0.79, p=0.003). The major reported toxicities in bevacizumab versus chemotherapy alone arms were grade 3/4 neutropenia (25.5% vs 16.8%), grade 3/4 hypertension (7% vs 0.7%), grade 3/4 proteinuria (3.1% vs 0%) and grade 3/4 haemorrhage (4.4% vs 0.7%). Out of the 17 treatment-related deaths, 15 were in bevacizumab arm VOL.13 NO. 8 AUGUST 2008 and 2 in chemotherapy alone arm, in which the 5 deaths related to haemoptysis were exclusively from the bevacizumab arm. This is the first landmark study to demonstrate superiority in combination of targeted therapy and chemotherapy compared to chemotherapy alone (standard-of-care) in the first-line treatment of patients with advanced NSCLC. In addition, another similar study has been conducted with the combination of bevacizumab and gemcitabine and cisplatin in advanced NSCLC (AVAiL study), with interim results suggesting favourable progression-free survival in the bevacizumab arm compared to chemotherapy alone arm.
Epidermal Growth Factor Receptor (EGFR) Inhibition
Upon disease progression after first-line chemotherapy treatment, docetaxel as monotherapy has been shown to be superior to best supportive care alone or alternative chemotherapy in survival. 12, 13 The newer chemotherapeutic agent, pemetrexed, has also been shown to have similar efficacy as docetaxel with lesser degree of adverse effects especially myelosuppression in the second-line setting. 14 However, this is still limited by the very modest improvement in median survival and also the toxicity profile in the second-line setting especially for those patients with poor performance status.
With advancement in molecular research, it becomes logical to target specific and crucial pathways involved in carcinogenesis to achieve better control of tumour growth while minimising the detrimental effects on normal body tissues. This concept of molecularly targeted therapy has been best exemplified by the inhibition of EGFR pathway in the treatment of NSCLC. The EGFR forms part of the signalling pathway that regulates tumour cell proliferation, invasion, angiogenesis, metastasis, and apoptosis. Since overexpression of EGFR is commonly found in NSCLC, various novel agents that inhibit EGFR pathway have been developed for treatment of this neoplasm. Apart from the use of monoclonal antibody that targets the EGFR extracellular binding site, small molecules that target the intracellular adenosine triphosphate (ATP) binding site of EGFR tyrosine kinase have been studied extensively.
Gefitinib (Iressa TM ) was the first EGFR tyrosine kinase inhibitor (TKI) used in the treatment of advanced NSCLC. Previous large-scale phase III trials (INTACT 1 and 2) failed to show clinical benefit by combining gefitinib with platinum-based chemotherapy in firstline treatment of advanced NSCLC. 15, 16 It was based on two large phase II trials (IDEAL 1 and 2) of gefitinib monotherapy in previously treated patients with advanced NSCLC that was approved as second-line treatment. 17, 18 From these trials, the objective response rate was up to 18% with encouraging median survival of 7-8 months, without the inclusion of a placebo arm. The most common toxicities were skin rash and diarrhoea, with rare occurrence of interstitial pneumonitis. Later a randomised, placebo-controlled, phase III study (ISEL) was reported on gefitinib versus placebo in treatment of advanced NSCLC patients who were refractory or intolerant to chemotherapy. 19 It was shown that gefitinib (250mg daily) was not associated with significant improvement in survival compared to placebo (median survival 5.6 vs 5.1 months in gefitinib vs placebo), despite some benefit among never smokers and patients of Asian descent. The commonest toxicities were skin rash (37%) and diarrhoea (27%). On the other hand, the preliminary results of a more recent phase III study of gefitinib versus docetaxel as second-line treatment for advanced NSCLC (INTEREST trial) suggested similar clinical efficacy between gefitinib and docetaxel.
Erlotinib (Tarceva   TM   ) is a later developed EGFR TKI that has also been extensively studied in treatment of NSCLC. Similar to gefitinib, large-scale phase III trials (TALENT and TRIBUTE) showed no clinical benefit in adding erlotinib to standard platinum-based chemotherapy as first-line treatment of advanced NSCLC. 20 A recent randomised, placebo-controlled, phase III trial of erlotinib versus placebo in treatment of advanced NSCLC after failure to previous chemotherapy was reported. 21 The erlotinib treatment arm was found to be superior in response rate (8.9% vs 1%), progression-free survival (2.2 vs 1.8 months) and overall survival (6.7 vs 4.7 months) compared to placebo arm. The more frequent adverse effects associated with erlotinib treatment were skin rash (76% vs 17%), anorexia (69% vs 56%), stomatitis (19% vs 3%), diarrhoea (55% vs 19%), ocular toxic effect (28% vs 9%) and infection (34% vs 21%) compared to placebo.
From the studies of gefitinib and erlotinib in treatment of advanced NSCLC, several clinical and molecular predicting factors for response to treatment were identified. 22 (Table 2 ) Specific mutations in the EGFR tyrosine kinase domain (exons 18-21) have been shown to be associated with treatment response, while other mutations might predict drug resistance. Therefore this class of novel agents is particularly effective in NSCLC patients with favourable characteristics (female, Asian descent, never smokers, adenocarcinoma, specific EGFR mutations), which often serve as the selection criteria for treatment. However, there are still controversies about the best molecular markers (either single or multiple) for response and survival outcome, and there is still lack of good predictors of the group with disease stabilisation after treatment.
Future Directions of Targeted Therapy in NSCLC
Targeting specific molecular signalling pathways remains a promising approach in the management of NSCLC. However there are still several issues that need to be addressed. First, there is a clear need of better characterisation of "targeted" patient subpopulation that may potentially benefit from a particular targeted approach. Future research in identifying biomarkers that reliably predict clinical treatment outcomes is warranted. Second, the potential use of EGFR TKI in clinical settings other than second or third-line in advanced NSCLC needs to better defined, especially in the adjuvant treatment for early-stage disease after curative lung resection or the first-line treatment for advanced disease.
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Third, the problem of acquired resistance to EGFR TKI (mostly related to a new mutation in EGFR) requires further research. In fact, there have been some newer generations of EGFR TKI that are currently under investigations for overcoming drug resistance to gefitinib or erlotinib. Last, as there has been better understanding about the potential interactions or crosstalks between different signalling pathways, it becomes logical to simultaneously target different molecular pathways in order to achieve better tumour control. As a result, there have been quite a number of multitargeted tyrosine kinase inhibitors (e.g. inhibiting both VEGF and EGFR) that are currently undergoing clinical trials in the treatment of NSCLC.
Conclusion
Although lung cancer, predominantly NSCLC, is still considered to be a devastating malignancy with 5-year survival less than 15%, there has been major advancement in the overall treatment especially in the era of targeted therapy. With our continuing efforts in research along the targeted approach, lung cancer will hopefully become a chronic condition like hypertension or diabetes in the near future. Table 2 Predictors for response to EGFR TKI in patients with advanced NSCLC*
